HCPCS code J7322: Hymovis billing, units, and Medicare coverage
Most denials on viscosupplementation claims trace back to two problems: wrong un...
Last Updated: Sep 4, 2026
Key takeaways
HCPCS code J7313 covers one brand only, Iluvien, the 0.19 mg fluocinolone acetonide implant from ANI Pharmaceuticals (Alimera Sciences).
One unit equals 0.01 mg, so a single Iluvien implant bills as 19 units on the claim line.
Yutiq has carried its own code, J7314, since October 1, 2019, and Retisert bills under J7311 at 59 units.
Medicare expects modifier JZ on the J7313 line to attest that no drug was discarded.
Iluvien’s label expanded on March 14, 2025 and now covers chronic non-infectious posterior uveitis as well as diabetic macular edema.
HCPCS code J7313 pays for exactly one product, and the official descriptor names it: injection, fluocinolone acetonide, intravitreal implant (Iluvien), 0.01 mg. One unit is 0.01 mg, so a single 0.19 mg implant bills as 19 units.
The brand name inside that descriptor does more work than it looks. Yutiq is the other fluocinolone acetonide implant, and it has had its own code since 2019. Putting one product on the other’s code is a denial, not a technicality.
This page covers what J7313 includes, how the 19 units are calculated, and the modifiers Medicare expects. It also sets out the diagnosis codes that support a claim, and the places where J7313 and J7314 still get mixed up.
Found our content helpful?
J7313 pays for one brand, and the descriptor names it
J7313 is a Level II drug code maintained by the Centers for Medicare and Medicaid Services (CMS). Its current descriptor reads:
Injection, fluocinolone acetonide, intravitreal implant (Iluvien), 0.01 mg
CMS put the brand name in the descriptor on purpose. Three products share the same active ingredient, and the code is how a payer tells them apart on a claim line.
J7313, J7314, and J7311 are three different products
All three codes describe fluocinolone acetonide in an intravitreal implant. They differ by product, dose, and unit count, and none of them substitutes for another. The dose is what drives the unit math, so the wrong code carries the wrong quantity with it.
Why Yutiq still turns up on J7313 claims
Yutiq launched in early 2019 without a product-specific code. For a few months it was billed under J7313, whose descriptor was brand-neutral at the time. CMS then created J7314 for Yutiq, effective October 1, 2019, and J7313 was revised to name Iluvien.
The guidance written during that short window never came down. North Carolina Medicaid, for one, published Yutiq billing instructions under J7313 in April 2019, and that bulletin still surfaces in search results. It predates J7314 by six months.
Payer policy has moved the other way since. UnitedHealthcare’s commercial drug policy for intravitreal corticosteroid implants, effective August 1, 2026, lists J7311, J7312, and J7313 and removed J7314 outright. ANI shifted US promotion from Yutiq to Iluvien during 2025, once the expanded Iluvien label covered the same uveitis indication.
J7314 is still an active HCPCS code, so a Yutiq implant still belongs on it. What has ended is any reason to reach for J7313 when the product in the applicator was Yutiq.
One implant is 19 units, never one unit
Divide the milligrams administered by 0.01 to get the units. One Iluvien implant holds 0.19 mg, so the J7313 line reads 19. ANI’s own billing and coding guide gives the same figure.
Billing 1 unit is not a rounding error. It asks the payer for 0.01 mg of a 0.19 mg implant. The line then pays roughly a nineteenth of what the drug cost the practice. Nothing in the remittance will say why.
There is no partial dose to worry about. Iluvien ships as a single-dose, preloaded applicator, so the quantity on the line is always 19. Treating both eyes on the same day means two implants and 38 units.
Iluvien’s label now covers DME and uveitis
Iluvien was a diabetic macular edema product for its first decade on the US market. On March 14, 2025, the FDA approved an expanded label that added chronic non-infectious uveitis affecting the posterior segment of the eye.
That change matters at the claim level. Coding references written before 2025 still describe Iluvien as DME-only. A biller following one of them may reject a legitimate uveitis claim before it reaches the payer.
Diabetic macular edema
Iluvien is indicated for DME in patients previously treated with a course of corticosteroids who did not have a clinically significant rise in intraocular pressure. That sentence is a documentation requirement, not clinical background.
Record the prior steroid course and the IOP readings that followed it. Commercial reviewers ask for both, and an appeal built on a chart that shows neither tends to fail.
Chronic non-infectious posterior uveitis
The 2025 addition covers chronic non-infectious uveitis of the posterior segment. Document that the uveitis is non-infectious in origin, because that single word separates a payable claim from a denied one.
This is the indication Yutiq was built for, which is exactly why the two products now blur together in billing. The code on the line, not the diagnosis, is what tells the payer which implant went in.
The diagnosis code has to match the indication and the eye
The ICD-10 code carries the medical necessity for a J7313 claim. ANI publishes the code families it expects for each indication, and both sets are laterality-specific. Report to the highest level of specificity the record supports.
Diabetic macular edema codes
The E08, E09, E10, and E13 categories carry the same four rows for the other diabetes types. Watch the tail of the code: anything that reads without macular edema will not support a DME claim, however accurate the retinopathy grade is.
Chronic non-infectious posterior uveitis codes
ANI’s guide lists further H30 subcategories for focal, peripheral, and generalized chorioretinal inflammation. Payer coverage lists are narrower than the label, so check the local coverage determination or the plan’s drug policy before the implant is ordered.
Modifier JZ belongs on almost every J7313 line
Iluvien arrives as a single-dose applicator, so nothing is left over to discard. CMS still wants that stated on the claim, and the modifier is how you state it.
Since July 1, 2023, Medicare has required either JW or JZ on separately payable Part B drugs supplied in single-dose containers. From October 1, 2023, claims that omit the modifier can be returned as unprocessable until they are corrected and resubmitted.
- JZ: zero drug discarded. This is the modifier a J7313 line normally carries, and ANI’s sample claim form shows it.
- JW: the discarded amount from a single-dose container. It has no routine use on J7313, since an implant cannot be part-administered.
- TB: acquired under 340B pricing, reported for information. Required on Medicare claims when the implant came through the 340B program.
- LT or RT: added to the administration CPT code to identify which eye was treated.
- 52: reduced services, used when part of the described procedure was not performed, such as no removal of vitreous.
Bilateral cases need a decision before submission. Payers differ on whether the administration goes out with modifier 50 or as separate LT and RT lines. Confirm the plan’s rule rather than assuming it.
Medicare pays J7313 at ASP plus 6%
Medicare Part B pays separately payable drugs at average sales price plus 6%. CMS republishes the ASP pricing file every quarter, so the allowed amount for J7313 moves four times a year. The formula is ASP multiplied by 1.06.
Check the current quarter before you order. Under buy-and-bill the practice pays for the implant first and is reimbursed only after the claim processes. A price that has moved since last quarter comes straight off the margin.
Commercial rates are negotiated separately and often use a different basis. Some plans pay a percentage of average wholesale price rather than ASP, which changes the acquisition math entirely. Reading an electronic remittance advice line by line is how billing teams catch the difference.
Pro Tip
Put the CMS ASP pricing file on a quarterly calendar reminder, dated a week before your usual reorder. Checking the current allowed amount takes minutes. It is also the last point in the cycle where a price drop can still be acted on.
Who bills the drug depends on the setting
In a physician office, place of service 11, the practice buys the implant and bills both J7313 and the administration code. The administration is paid at the non-facility rate, which includes the practice expense of doing the procedure.
In a hospital outpatient department or an ambulatory surgical center, the facility buys and bills the implant. The physician bills only the administration, at the facility rate. Hospitals report the drug under revenue code 0636 and the procedure under 0361.
Run buy-and-bill in this order
Buy-and-bill means the practice purchases the implant, administers it, then bills for the drug and the procedure. Understanding medical billing fundamentals helps, but the sequence below is what protects the money.
- Verify eligibility and coverage before ordering. Confirm active Part B coverage, or that J7313 is a covered benefit under the commercial plan. Insurance eligibility verification tools return benefit detail in real time.
- Obtain prior authorization where the payer requires it, and record the authorization number in the chart before the appointment is confirmed.
- Acquire the implant from a specialty distributor. Log the acquisition price, the lot number, the expiry date, and the NDC printed on the carton.
- Administer and document the implant: brand, dose, eye treated, date of service, and the treating provider’s NPI.
- Submit the claim with J7313 at 19 units and modifier JZ. Add the NDC where the payer wants it, the administration CPT code with LT or RT, and the supporting diagnosis.
- Reconcile the remittance against the expected ASP plus 6% allowed amount, and route underpayments into your revenue cycle management review.
A complete superbill at step five saves the back-and-forth at step six. One clean submission beats two appeals every time.
Prior authorization depends entirely on the payer
Treating every payer the same is the most reliable way to generate avoidable denials on this code. The requirements split three ways.
- Medicare Part B: fee-for-service generally does not require prior authorization for buy-and-bill drugs. Medicare Advantage plans set their own rules, so check the specific plan.
- Medicaid: requirements are set state by state. Several programs require prior authorization with supporting diagnosis documentation, and some apply step therapy first.
- Commercial plans: prior authorization is the norm. Expect requests for chart notes, the prior corticosteroid course for a DME claim, and IOP history.
Published criteria show how specific this gets. UnitedHealthcare’s commercial policy, effective August 1, 2026, treats Iluvien as proven for chronic non-infectious posterior uveitis. It is also proven for DME after a prior corticosteroid course with no clinically significant IOP rise. The policy caps the dose at one implant per eye and the authorization at 60 days.
A 60-day authorization window is short enough to expire between approval and surgery date. Building that check into scheduling, rather than into the day of service, is what medical billing compliance looks like in practice.
Six errors behind most J7313 denials
Each of these turns up in ophthalmology billing regularly, and each has a fix that takes less time than the appeal.
Error 1: billing 1 unit instead of 19
The line is quantity-driven, not product-driven. Put the unit count on a reference card at the charge-capture step, next to the 18 for J7314 and the 59 for J7311.
Error 2: billing Yutiq under J7313
Yutiq belongs on J7314 at 18 units, and has done since October 2019. Anyone working from a 2019 payer bulletin will get this wrong, so date-check the source before you trust it.
Error 3: billing Retisert under J7313
Retisert holds 0.59 mg and bills under J7311 at 59 units. Same active ingredient, different product, different code. Other coding families work the same way, as the CCSD procedure codes reference shows.
Error 4: leaving JZ off the line
A missing wastage modifier can send the claim back as unprocessable rather than denied, which means it never enters the appeal queue. Make JZ a required field on the charge line for this code.
Error 5: a diagnosis that does not support the implant
Two versions of this show up. One is a retinopathy code that says without macular edema. The other is a laterality mismatch, where the diagnosis names the right eye and the operative note names the left.
Error 6: submitting the drug without the administration code
J7313 pays for the implant only. Leaving the administration CPT code off the claim quietly forfeits the procedure payment, and nobody notices because the claim still pays. Good denial management catches the first five errors, but not this one.
The codes that travel with J7313 on a claim
J7313 covers the drug. The injection is billed separately, and the neighboring J-codes exist so that a payer can tell four ophthalmic implants apart.
The administration code is worth a second look. Most payers and the American Academy of Ophthalmology point to CPT 67028 for an injected implant. ANI’s billing guide lists both 67027 and 67028, and shows 67027 on its sample claim form. Check the policy before the first claim of the year goes out.
Pro Tip
Set your billing system to reject a J7313 charge line that has no administration code attached to the same date of service. The drug claim pays perfectly well on its own, which is exactly why a missing injection code can go unnoticed for months.
How Pabau keeps J7313 claims moving
In most ophthalmology practices the implant is recorded in one system and the claim is built in another. Someone reads the note, works out the units, and retypes the NDC into a billing screen. Each hop is a chance to lose a digit.
Practice management software like Pabau closes that hop. The treatment note, the diagnosis, the product used, and the invoice sit in one client record. From there, claims management software builds the claim from what the clinician documented. In the US, claims route through Claim.MD, with eligibility checks, claim status, and remittance posting landing against the same record.
It does not make the coding decisions for you. Pabau will not choose the modifier or judge whether the diagnosis supports the indication. No software replaces a biller who has read the payer policy. What it removes is the retyping between the record and the claim.
Turn an implant administration into a clean claim
Pabau keeps the treatment note, the diagnosis, and the invoice in one client record, then submits the claim electronically. Your billers work from what the clinician documented instead of retyping it into a second system.
Conclusion
J7313 is a simple code with one expensive trap in it. The descriptor names Iluvien, and only Iluvien, at 19 units per implant. Yutiq has been billed on J7314 since 2019, whatever a surviving 2019 bulletin says.
The rest is routine. Put JZ on the line and match the diagnosis to the indication and the eye. Check the quarterly ASP before you order, and bill the administration code alongside the drug.
Get those four right and J7313 stops being a denial risk. To see how Pabau carries an implant administration straight through to a submitted claim, book a demo.
Continue your research
Want to understand how clearinghouse submissions work for drug codes? Medical claims clearinghouse overview explains how electronic claims route from practice to payer and where J-code claims can stall.
Need to strengthen your denial prevention process? Denial codes in medical billing covers the most common remittance denial reasons and how to address each one before resubmission.
Looking for guidance on documentation requirements for specialty drugs? Getting credentialed with insurance companies walks through payer enrollment steps that affect drug reimbursement eligibility.
Frequently asked questions
What is HCPCS code J7313 used for?
J7313 bills the Iluvien fluocinolone acetonide intravitreal implant, 0.19 mg, administered into the eye. One unit equals 0.01 mg, so a single implant is reported as 19 units.
Is Yutiq billed under J7313?
No. Yutiq has had its own code, J7314, since October 1, 2019, and it bills at 18 units. Any guidance pairing Yutiq with J7313 predates that code.
Does J7313 need modifier JW or JZ?
JZ. It attests that no drug was discarded, which is always the case with a single-dose implant. Medicare has required JW or JZ on these lines since July 1, 2023.
Which ICD-10 codes support a J7313 claim?
Laterality-specific diabetic retinopathy codes with macular edema, such as E11.3211, or posterior uveitis codes such as H30.021 and H44.111. Individual payer policies list narrower sets.
What does Medicare pay for J7313?
Average sales price plus 6%, recalculated each quarter from the CMS ASP pricing file. Check the current quarter’s allowed amount before each purchase, because the rate moves four times a year.
Which CPT code is billed with J7313?
CPT 67028 for the intravitreal injection, with LT or RT to show the eye treated. ANI’s billing guide also lists 67027, so confirm which one the payer wants.
Does J7313 require prior authorization?
Medicare fee-for-service generally does not. Medicare Advantage, Medicaid, and commercial plans usually do, and commercial criteria often cap the authorization at 60 days and one implant per eye.
Found our content helpful?
